Press "Enter" to skip to content

Exclusive Report on Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market 2019 | Industry Drivers, Business Plans, Types, Applications, Challenges, Opportunities and Latest Trends Forecast to 2024

Sodium-dependent

The “Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Are:

  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999739

    Market Overview:

  • The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
  • The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
  • The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.

    Scope of the Report:

  • The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.

    Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the key market trends impacting the growth of the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the market opportunities and threats faced by the vendors in the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999739

    Key Market Trends: – Jardiance is Leading the SGLT2 Market.

    Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
    Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
    Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).

    65% of the Market Share is Occupied by North America.
    The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
    The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
    In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Sodium-dependent Glucose Co-transporter 2 (SGLT 2).

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999739

    Report Objectives:

    • Analyzing the size of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market.
    • Determining the key dynamics of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market.
    • Highlighting significant trends of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market.

    Detailed TOC of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
    5.1.1.1 Invokana (Canagliflozin)
    5.1.1.2 Jardiance (Empagliflozin)
    5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4 Suglat (Ipragliflozin)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Eli Lilly
    7.1.2 Janssen Pharmaceuticals
    7.1.3 Astellas
    7.1.4 Boehringer Ingelheim
    7.1.5 AstraZeneca
    7.1.6 Bristol Myers Squibb
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Eli Lilly
    7.2.2 Janssen Pharmaceuticals
    7.2.3 Astellas
    7.2.4 Boehringer Ingelheim
    7.2.5 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Abrasive Paper Market 2019-2023 By Future Demands, Development Strategy, Size, Share, Sales-Revenue, Growth Factors, Industry Updates and Key Players Analysis Available at Industry Research Biz

    Sodium Methoxide Market 2019-2024: Global Industry Size, Share, Emerging Trends, Demand, Revenue and Forecasts Research

    Global Solid Phase Extraction Market Size 2019 | Research Methodology, Top Manufactures and Market Size Estimate 2023

    Global Healthcare IT Market 2024 by Growth Rate, Price, Share, Revenue, Historical Analysis, Segmentation, Types, Applications and Forecast Analysis of Key Players

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *